PHGE Stock Summary and Trading Ideas (Biomx | AMEX:PHGE)

BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).

Biomx trades on the AMEX stock market under the symbol PHGE.

As of December 17, 2025, PHGE stock price climbed to $1.71 with 68,675 million shares trading.

PHGE has a beta of 0.93, meaning it tends to be less sensitive to market movements. PHGE has a correlation of 0.02 to the broad based SPY ETF.

PHGE has a market cap of $2.61 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, PHGE traded as high as $162.45 and as low as $1.50.

PHGE has underperformed the market in the last year with a price return of -86.5% while the SPY ETF gained +11.8%. PHGE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -81.5% and -63.6%, respectively, while the SPY returned +2.0% and -1.5%, respectively.

PHGE support price is $1.36 and resistance is $1.74 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PHGE shares will trade within this expected range on the day.